Real-World Results of GLP-1 Drugs for Overweight Diabetes Patients in Romania

In 311 Romanian patients with type 2 diabetes and excess weight, GLP-1 drugs improved blood sugar, body weight, and waist circumference in real-world practice.

Popoviciu, Mihaela Simona et al.·Biomedicines·2025·low-moderateObservational
RPEP-13087Observationallow-moderate2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Observational
Evidence
low-moderate
Sample
N=N=311
Participants
Romanian adults with type 2 diabetes, HbA1c >7.2%, and BMI >=25

What This Study Found

All GLP-1 RAs studied improved HbA1c, body weight, and waist circumference in real-world Romanian clinical practice.

Key Numbers

N=311; HbA1c >7.2% and BMI >=25 at baseline; all treatments significantly improved HbA1c, BMI, and WC at 6 months (p values significant).

How They Did This

Prospective observational study of 311 T2DM adults monitoring HbA1c, body weight, and waist circumference on various GLP-1 RAs.

Why This Research Matters

Clinical trial results don't always translate to real-world settings — this confirms GLP-1 drug effectiveness in routine Romanian clinical practice.

The Bigger Picture

Real-world data from diverse healthcare systems strengthens the global evidence base for GLP-1 drug guidelines.

What This Study Doesn't Tell Us

Observational design without control group. Single-country cohort may not generalize to all healthcare settings.

Questions This Raises

  • ?Which GLP-1 RA performed best in this Romanian cohort?
  • ?Do results differ between oral and injectable semaglutide in real-world use?

Trust & Context

Key Stat:
311 patients Prospective real-world Romanian cohort on 4 different GLP-1 receptor agonists
Evidence Grade:
Prospective observational study — better than retrospective but lacks randomization and control group.
Study Age:
Published in 2025, reflecting current GLP-1 prescribing patterns in Romania.
Original Title:
Translating Guidelines into Practice: A Prospective Real-World Study of a Romanian Cohort Treated with GLP-1 RAs.
Published In:
Biomedicines, 13(9) (2025)
Database ID:
RPEP-13087

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Watches what happens naturally without intervening.

What do these levels mean? →

Frequently Asked Questions

Do GLP-1 drugs work as well in real life as in clinical trials?

This Romanian study confirms real-world improvements in blood sugar, weight, and waist circumference across multiple GLP-1 medications.

Which GLP-1 drug is best?

The study compared exenatide, semaglutide (oral and injectable), and dulaglutide — all showed effectiveness in real-world use.

Read More on RethinkPeptides

Cite This Study

RPEP-13087·https://rethinkpeptides.com/research/RPEP-13087

APA

Popoviciu, Mihaela Simona; Reurean-Pintilei, Delia; Salmen, Teodor; Rus, Marius; Ferician, Anca; Sava, Cristian; Ardelean, Adriana Ioana; Moroianu, Lavinia-Alexandra; Pantea Stoian, Anca. (2025). Translating Guidelines into Practice: A Prospective Real-World Study of a Romanian Cohort Treated with GLP-1 RAs.. Biomedicines, 13(9). https://doi.org/10.3390/biomedicines13092174

MLA

Popoviciu, Mihaela Simona, et al. "Translating Guidelines into Practice: A Prospective Real-World Study of a Romanian Cohort Treated with GLP-1 RAs.." Biomedicines, 2025. https://doi.org/10.3390/biomedicines13092174

RethinkPeptides

RethinkPeptides Research Database. "Translating Guidelines into Practice: A Prospective Real-Wor..." RPEP-13087. Retrieved from https://rethinkpeptides.com/research/popoviciu-2025-translating-guidelines-into-practice

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.